Followers | 283 |
Posts | 1162 |
Boards Moderated | 0 |
Alias Born | 10/04/2020 |
Thursday, April 22, 2021 5:45:33 PM
SEC LINK:
https://sec.report/Document/0001607062-21-000077/rgbp040721form8l.htm?__cf_chl_jschl_tk__=db65aaa100f06b4601b11ccc9f65a1fba9e35127-1619126957-0-AVcxvKc-we5PhYJrQxSZJ3zxfOXe4_KOFxhHcEbp0aIUFfbHIel_FiOMMyP4wafsj88fnjpXysHvLLY8lXpRlmKzd6bdZEJvOMGVPL2wxnYZKrf4Ud9GMfo63TCbnRPDGVe4y4qdCps9LT2hV2inDDnmRslwuK_--xqUOu8OzvWfZciFEk6fdzTwJ9pzj8Xn70Ja8ZlzXw0WnZX-rKrWHbD20YCXk7f9slpOpVLVVFTd9IBJI-RirT32Lw-m14NpbdP-xET8A3qpXwlGC5nLyUUDvRUr4K0gG65Q-AXnSaU0X5oBNunml22BltfWP8jwmLQQZuQTD_GCNQQIFJ4dzrHkeJgSNhi3lh_bjuyKccjbfa5vms4UHcr0se61YlC3VUc5EB5s4X4UWNqO_JIJFhIqZOUwNg2KcaEMHGuXjjhXXc4sxwvbmt1XgyLgeR_VeKMQhTFbEbMqCLFJycJ-uDkSj9_hzlUGnCGhc6tYkOffYiNL3SnFbsCbMVjzuw47Bg
On April 7, 2021 Regen Biopharma, Inc. (“Regen”) entered into an agreement (“Agreement”) with Oncology Pharma, Inc. (“Licensee”) whereby Regen granted to Licensee an exclusive right and license for the development and commercialization of certain intellectual property ( “License IP”) for the treatment in humans of Pancreatic Cancer for a term of fifteen years from April 7, 2021.
The License IP consists of antigen specific cancer vaccines in which modified mRNA is administered to produce epitopes able to produce an immune response which augments likelihood of successful induction of immunity. An epitope is the part of an antigen that is recognized by the immune system.
As consideration to Regen for the rights and license granted pursuant to the Agreement Licensee shall:
(a) pay to Regen a nonrefundable fee of $55,000 no later than April 20,2021
(b) pay to Regen royalties equal to five percent (5%) of the Net Sales as Net Sales are defined in the Agreement of any Licensed Products in a quarter.
(c) pay to Regen ten percent (10%) of all consideration (in the case of in-kind consideration, at fair market value as monetary consideration) received by Licensee from sublicensees, excluding royalties from sublicensees based on Net Sales of any Licensed Products for which Regen receives payment.
Licensed Product is defined in the Agreement as (a) any method, procedure, service or process that incorporates, uses, used, is covered by, infringes or would infringe any of the License IP in the U.S. or foreign jurisdictions; and (b) any apparatus, material, equipment, machine or other product that incorporates, uses, used, is covered by, infringes or would infringe any of the License IP in the U.S. or foreign jurisdictions but for the rights granted pursuant to the Agreement.
In the event that development of the License IP by the Licensee is not commenced as of the date that is nine months from the effective date of the Agreement the rights and license granted pursuant to the Agreement shall become nonexclusive.
The foregoing description of the Agreement is not complete and is qualified in its entirety by reference to the text of the Agreement , which is attached to this Current Report on Form 8-K as Exhibit 10.1 and incorporated in this Item 1.01 by reference.
On April 7, 2021 KCL Therapeutics, Inc. (“KCL”), a subsidiary of Regen Biopharma, Inc., entered into an agreement (“Agreement”) with Oncology Pharma, Inc. (“Licensee”) whereby KCL granted to Licensee an exclusive right and license for the development and commercialization of certain intellectual property (“License IP”) for the treatment in humans of Colon Cancer for a term of fifteen years from April 7, 2021.
As consideration to KCL for the rights and license granted pursuant to the Agreement Licensee shall:
(a) pay to KCL a nonrefundable fee of Fifty Thousand common shares of Oncology Pharma, Inc. no later than April 20,2021
(b) pay to KCL royalties equal to five percent (5%) of the Net Sales as Net Sales are defined in the Agreement of any Licensed Products in a quarter.
(c) pay to KCL ten percent (10%) of all consideration (in the case of in-kind consideration, at fair market value as monetary consideration) received by Licensee from sublicensees, excluding royalties from sublicensees based on Net Sales of any Licensed Products for which KCL receives payment.
Licensed Product is defined in the Agreement as (a) any method, procedure, service or process that incorporates, uses, used, is covered by, infringes or would infringe any of the License IP in the U.S. or foreign jurisdictions; and (b) any apparatus, material, equipment, machine or other product that incorporates, uses, used, is covered by, infringes or would infringe any of the License IP in the U.S. or foreign jurisdictions but for the rights granted pursuant to the Agreement.
In the event that development of the License IP by the Licensee is not commenced as of the date that is nine months from the effective date of the Agreement the rights and license granted pursuant to the Agreement shall become nonexclusive.
KCL Therapeutics, Inc. is a wholly owned subsidiary of Regen Biopharma, Inc.
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM
Element79 Gold Corp Files for OTCQB Uplisting, Provides Financial Update • ELEM • Jun 11, 2024 9:25 AM
Southern Silver Announces Updated PEA on Cerro Las Minitas: US$501M After-tax NPV5%; 21% IRR; 48 Month payback • SSV • Jun 11, 2024 5:26 AM
Swifty Global Announces South African Gambling License Approval • DRCR • Jun 10, 2024 9:15 AM
DaBaby and Stunna 4 Vegas's "NO DRIBBLE" Joins Music Licensing, Inc.'s Portfolio • SONGD • Jun 7, 2024 10:15 AM